Othman Ahmed A, Chatamra Krai, Mohamed Mohamed-Eslam F, Dutta Sandeep, Benesh Janet, Yanagawa Masayoshi, Nagai Masahiro
Clinical Pharmacology and Pharmacometrics, AbbVie, 1 North Waukegan Road, Building AP13A-3, North Chicago, IL, 60064, USA,
Clin Pharmacokinet. 2015 Sep;54(9):975-84. doi: 10.1007/s40262-015-0265-3.
Oral levodopa-carbidopa (LC-oral) treatment in advanced Parkinson's disease (PD) is associated with motor complications due to large fluctuations in levodopa plasma concentrations. Levodopa-carbidopa intestinal gel (LCIG) provides individualized continuous levodopa-carbidopa delivery through intrajejunal infusion. This study evaluated the pharmacokinetics, safety, and efficacy of LCIG relative to LC-oral in Japanese subjects with advanced PD.
Subjects with advanced PD were converted from their anti-PD medications to individually optimized doses of LC-oral (10:1 levodopa:carbidopa ratio) for 28 days (baseline; period 1) followed by switching to intrajejunal infusion of LCIG (4:1 ratio) for 21 days (period 2). Pharmacokinetics, adverse events (AEs), and efficacy were assessed.
Eight patients were enrolled. Six received LCIG and four reported at least one AE [most common: fall (33.3 %), dyskinesia (33.3 %)]; one discontinued due to an AE. The average daily dose was 1230/123 and 1370/342 mg levodopa/carbidopa for LC-oral and LCIG, respectively, at the end of each period. The degree of fluctuation and intra-subject variability of levodopa plasma concentrations were 5.5- and 4-fold lower, respectively, with LCIG than with LC-oral. Levodopa bioavailability was 99 % for LCIG relative to LC-oral. Compared with baseline, LCIG decreased "Off" time (2.68 h, P = 0.002) and increased "On" time without troublesome dyskinesia (2.35 h, P = 0.006) in the PD Diary(©). With the small sample size, no statistically significant changes were seen on other efficacy endpoints.
In Japanese subjects with advanced PD, LCIG resulted in an improved pharmacokinetic profile that appeared to be associated with reduced motor complications compared with LC-oral. These results extend previous findings in mainly Caucasian populations.
在晚期帕金森病(PD)中,口服左旋多巴 - 卡比多巴(LC - 口服)治疗会因左旋多巴血浆浓度大幅波动而引发运动并发症。左旋多巴 - 卡比多巴肠凝胶(LCIG)通过空肠内输注实现个体化的持续左旋多巴 - 卡比多巴给药。本研究评估了在日本晚期PD患者中,LCIG相对于LC - 口服的药代动力学、安全性及疗效。
晚期PD患者停用抗PD药物,转换为个体化优化剂量的LC - 口服(左旋多巴:卡比多巴比例为10:1),持续28天(基线期;第1阶段),随后转换为空肠内输注LCIG(比例为4:1),持续21天(第2阶段)。评估药代动力学、不良事件(AE)及疗效。
共纳入8例患者。6例接受LCIG治疗,4例报告至少发生1次AE[最常见的为跌倒(33.3%)、异动症(33.3%)];1例因AE停药。在每个阶段结束时,LC - 口服和LCIG的左旋多巴/卡比多巴平均日剂量分别为1230/123和1370/342 mg。与LC - 口服相比,LCIG使左旋多巴血浆浓度的波动程度和个体内变异性分别降低了5.5倍和4倍。相对于LC - 口服而言,LCIG的左旋多巴生物利用度为99%。与基线相比,在帕金森病日记(©)中,LCIG减少了“关”期时间(2.68小时,P = 0.002),并增加了无严重异动症的“开”期时间(2.35小时,P = 0.006)。由于样本量较小,在其他疗效终点上未观察到统计学上的显著变化。
在日本晚期PD患者中,与LC - 口服相比,LCIG改善了药代动力学特征,且似乎与运动并发症减少相关。这些结果扩展了之前主要在白种人群中的研究发现。